MX373392B - Nuevos derivados de quinolona. - Google Patents
Nuevos derivados de quinolona.Info
- Publication number
- MX373392B MX373392B MX2015008233A MX2015008233A MX373392B MX 373392 B MX373392 B MX 373392B MX 2015008233 A MX2015008233 A MX 2015008233A MX 2015008233 A MX2015008233 A MX 2015008233A MX 373392 B MX373392 B MX 373392B
- Authority
- MX
- Mexico
- Prior art keywords
- quinolone derivatives
- new quinolone
- preparation
- compounds
- formula
- Prior art date
Links
- 150000007660 quinolones Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
- C07D215/60—N-oxides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Quinoline Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3600MU2012 | 2012-12-24 | ||
| PCT/IN2013/000796 WO2014102818A1 (en) | 2012-12-24 | 2013-12-23 | Novel quinolone derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015008233A MX2015008233A (es) | 2015-09-29 |
| MX373392B true MX373392B (es) | 2020-04-20 |
Family
ID=54148255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008233A MX373392B (es) | 2012-12-24 | 2013-12-23 | Nuevos derivados de quinolona. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9394300B2 (enExample) |
| EP (1) | EP2935221B1 (enExample) |
| JP (1) | JP6026013B2 (enExample) |
| KR (1) | KR101733901B1 (enExample) |
| CN (1) | CN104903295B (enExample) |
| AP (1) | AP2015008502A0 (enExample) |
| AR (1) | AR094300A1 (enExample) |
| AU (1) | AU2013368843B2 (enExample) |
| BR (1) | BR112015014222B1 (enExample) |
| CA (1) | CA2894636C (enExample) |
| CL (1) | CL2015001802A1 (enExample) |
| EA (1) | EA028402B1 (enExample) |
| ES (1) | ES2660288T3 (enExample) |
| IL (1) | IL239109B (enExample) |
| JO (1) | JO3781B1 (enExample) |
| MA (1) | MA38138A1 (enExample) |
| MX (1) | MX373392B (enExample) |
| MY (1) | MY175854A (enExample) |
| NZ (1) | NZ708605A (enExample) |
| PH (1) | PH12015501452B1 (enExample) |
| SG (1) | SG11201504458XA (enExample) |
| TR (1) | TR201802305T4 (enExample) |
| TW (1) | TWI598339B (enExample) |
| UA (1) | UA117122C2 (enExample) |
| WO (1) | WO2014102818A1 (enExample) |
| ZA (1) | ZA201503814B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016034108A1 (zh) * | 2014-09-02 | 2016-03-10 | 广东东阳光药业有限公司 | 喹啉酮类化合物及其应用 |
| WO2016045125A1 (en) | 2014-09-28 | 2016-03-31 | Merck Sharp & Dohme Corp. | Inhibitors of hif prolyl hydroxylase |
| CL2015003047A1 (es) * | 2015-10-15 | 2016-06-17 | Univ Chile | Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| CN108069957B (zh) * | 2016-11-09 | 2022-11-04 | 广东东阳光药业有限公司 | 脯氨酰羟化酶抑制剂及其用途 |
| CA3062972C (en) | 2017-05-09 | 2021-09-14 | Kind Pharmaceutical | Indolizine derivatives and their application in medicine |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| TW202200547A (zh) * | 2020-03-13 | 2022-01-01 | 印度商卡地拉保健有限公司 | 喹啉酮化合物的新穎鹽類 |
| EP4121009A4 (en) * | 2020-03-17 | 2024-04-17 | Zydus Lifesciences Limited | Formulation comprising hif prolyl hydroxylase inhibitors |
| EP4138825A1 (en) | 2020-04-20 | 2023-03-01 | Akebia Therapeutics Inc. | Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer |
| EP4157233A4 (en) * | 2020-05-29 | 2024-06-26 | Zydus Lifesciences Limited | TREATMENT OF PSORIASIS AND INFLAMMATORY SKIN DISEASES |
| CN115666517A (zh) * | 2020-06-01 | 2023-01-31 | 兹杜斯生命科学有限公司 | 炎性肠病的治疗 |
| WO2022150623A1 (en) | 2021-01-08 | 2022-07-14 | Akebia Therapeutics, Inc. | Compounds and composition for the treatment of anemia |
| BR112023018949A2 (pt) * | 2021-03-19 | 2023-10-17 | Zydus Lifesciences Ltd | Composto, uso do mesmo para tratar anemia falciforme e composição farmacêutica compreendendo o referido composto |
| EP4308089A4 (en) * | 2021-03-19 | 2025-02-26 | Zydus Lifesciences Limited | QUINOLONE COMPOUND IN SOLID FORMS AND PROCESSES FOR THEIR PREPARATION |
| WO2022238745A1 (en) * | 2021-05-14 | 2022-11-17 | Zydus Lifesciences Limited | Topical pharmaceutical composition of hif prolyl hydroxylase inhibitors |
| TW202313072A (zh) | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | 檸檬酸鐵之兒科調配物 |
| CN113549011B (zh) * | 2021-08-10 | 2023-05-09 | 广东东阳光药业有限公司 | 德度司他的共晶或盐及其制备方法和用途 |
| WO2023042170A1 (en) * | 2021-09-20 | 2023-03-23 | Zydus Lifesciences Limited | Desidustat particles and compositions thereof |
| EP4539934A1 (en) * | 2022-06-24 | 2025-04-23 | Zydus Lifesciences Limited | Treatment for glomerular diseases |
| WO2024028744A1 (en) * | 2022-08-01 | 2024-02-08 | Zydus Lifesciences Limited | Treatment for aplastic anemia (aa) |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ270267A (en) | 1993-12-30 | 1997-03-24 | Hoechst Ag | 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions |
| PL1644336T3 (pl) | 2003-06-06 | 2011-07-29 | Fibrogen Inc | Związki heteroarylowe zawierające azot i ich zastosowanie w zwiększaniu poziomu endogennej erytropoetyny |
| CN101166745A (zh) * | 2005-03-02 | 2008-04-23 | 菲布罗根有限公司 | 噻吩并吡啶化合物和其使用方法 |
| WO2007038571A2 (en) * | 2005-09-26 | 2007-04-05 | Smithkline Beecham Corporation | Prolyl hydroxylase antagonists |
| JP5202327B2 (ja) | 2005-12-09 | 2013-06-05 | アムジエン・インコーポレーテツド | プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用 |
| AR059733A1 (es) * | 2006-03-07 | 2008-04-23 | Smithkline Beecham Corp | Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion |
| CA2647596C (en) * | 2006-04-04 | 2012-06-12 | Fibrogen, Inc. | Pyrrolo- and thiazolo-pyridine compounds as hif modulators |
| WO2007136990A2 (en) * | 2006-05-16 | 2007-11-29 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| EP2044068A4 (en) * | 2006-07-17 | 2010-07-21 | Merck Sharp & Dohme | 1-HYDROXY Naphthyridine Compounds as Anti- HIV Drugs |
| WO2008076425A1 (en) | 2006-12-18 | 2008-06-26 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| ES2442847T3 (es) * | 2007-04-18 | 2014-02-13 | Amgen, Inc | Quinolonas y azaquinolonas que inhiben la prolil hidroxilasa |
| EP2136810A4 (en) * | 2007-04-18 | 2012-01-04 | Merck Sharp & Dohme | NOVEL 1,8-NAPHTHYRIDINE COMPOUNDS |
| AU2008248234B2 (en) * | 2007-05-04 | 2011-02-03 | Amgen Inc. | Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity |
| AU2008248165B2 (en) * | 2007-05-04 | 2011-12-08 | Amgen Inc. | Diazaquinolones that inhibit prolyl hydroxylase activity |
| AU2008251031B2 (en) * | 2007-05-16 | 2013-12-19 | Norman Terry Cowper | System and method for maximising solids concentration of slurry pumped through a pipeline |
| AU2008329746A1 (en) * | 2007-11-30 | 2009-06-04 | Glaxosmithkline Llc | Prolyl hydroxylase inhibitors |
| JP2011513222A (ja) * | 2008-02-25 | 2011-04-28 | メルク・シャープ・エンド・ドーム・コーポレイション | テトラヒドロチエノピリジン |
| JP2011513223A (ja) * | 2008-02-25 | 2011-04-28 | メルク・シャープ・エンド・ドーム・コーポレイション | テトラヒドロ−１ｈ−ピロロ縮合ピリドン |
| CN101951777A (zh) * | 2008-02-25 | 2011-01-19 | 默沙东公司 | 四氢呋喃并吡啶酮 |
| WO2009158315A1 (en) * | 2008-06-25 | 2009-12-30 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| DK2455381T5 (en) | 2009-07-17 | 2015-02-09 | Japan Tobacco Inc | Triazolopyridinforbindelse and its effect as an inhibitor of prolyl hydroxylase and induce erythropoietin production by |
| EP2467361A1 (de) * | 2009-08-20 | 2012-06-27 | Vifor (International) Ag | Neue chinolin-hepcidin-antagonisten |
| EP2670750B1 (en) | 2011-02-02 | 2016-09-14 | Fibrogen, Inc. | Naphthyridine derivatives as inhibitors of hypoxia inducible factor |
| WO2013043621A1 (en) | 2011-09-23 | 2013-03-28 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
| EP2810944A1 (en) * | 2012-01-31 | 2014-12-10 | Toyama Chemical Co., Ltd. | Heterocyclic compound having anti-hiv activity |
-
2013
- 2013-12-23 AU AU2013368843A patent/AU2013368843B2/en active Active
- 2013-12-23 US US14/652,024 patent/US9394300B2/en active Active
- 2013-12-23 BR BR112015014222-2A patent/BR112015014222B1/pt active IP Right Grant
- 2013-12-23 SG SG11201504458XA patent/SG11201504458XA/en unknown
- 2013-12-23 CA CA2894636A patent/CA2894636C/en active Active
- 2013-12-23 ES ES13828997.0T patent/ES2660288T3/es active Active
- 2013-12-23 TW TW102147766A patent/TWI598339B/zh active
- 2013-12-23 EA EA201591195A patent/EA028402B1/ru not_active IP Right Cessation
- 2013-12-23 AP AP2015008502A patent/AP2015008502A0/xx unknown
- 2013-12-23 CN CN201380067856.4A patent/CN104903295B/zh active Active
- 2013-12-23 NZ NZ708605A patent/NZ708605A/en unknown
- 2013-12-23 UA UAA201506784A patent/UA117122C2/uk unknown
- 2013-12-23 JO JOP/2013/0383A patent/JO3781B1/ar active
- 2013-12-23 KR KR1020157016080A patent/KR101733901B1/ko active Active
- 2013-12-23 WO PCT/IN2013/000796 patent/WO2014102818A1/en not_active Ceased
- 2013-12-23 TR TR2018/02305T patent/TR201802305T4/tr unknown
- 2013-12-23 MX MX2015008233A patent/MX373392B/es active IP Right Grant
- 2013-12-23 EP EP13828997.0A patent/EP2935221B1/en active Active
- 2013-12-23 MY MYPI2015001457A patent/MY175854A/en unknown
- 2013-12-23 JP JP2015548889A patent/JP6026013B2/ja active Active
- 2013-12-27 AR ARP130105055A patent/AR094300A1/es active IP Right Grant
-
2015
- 2015-05-27 ZA ZA2015/03814A patent/ZA201503814B/en unknown
- 2015-05-29 MA MA38138A patent/MA38138A1/fr unknown
- 2015-06-01 IL IL239109A patent/IL239109B/en active IP Right Grant
- 2015-06-22 CL CL2015001802A patent/CL2015001802A1/es unknown
- 2015-06-23 PH PH12015501452A patent/PH12015501452B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX373392B (es) | Nuevos derivados de quinolona. | |
| PH12020550552A1 (en) | Inhibitors of hepatitis c virus | |
| MD20140063A2 (ro) | Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV | |
| PH12016500885A1 (en) | Novel heterocyclic compounds | |
| EA201590931A1 (ru) | Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций | |
| PH12014502040A1 (en) | Heterocyclyl compounds | |
| UA113651C2 (xx) | Макроциклічні пурини для лікування вірусних інфекцій | |
| EA201492287A1 (ru) | Дейтерированные производные руксолитиниба | |
| MX353806B (es) | Quinolinas como moduladores de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr). | |
| GEP20176631B (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| IN2014CN04530A (enExample) | ||
| PH12012500622A1 (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| JO3115B1 (ar) | مركبات بيريدازينون واستخدامها كمثبطات daao | |
| EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
| MX2016003522A (es) | Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa. | |
| PH12014501943A1 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| PH12013500671A1 (en) | Novel gpr 119 agonists | |
| IN2015DN02109A (enExample) | ||
| UA111851C2 (uk) | Сполуки піридазинону та їх використання як інгібіторів daao | |
| TN2014000077A1 (en) | Pyridazinone compounds and their use as daao inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |